Avenue Therapeutics, Inc. (ATXI): Price and Financial Metrics


Avenue Therapeutics, Inc. (ATXI): $0.25

-0.02 (-6.35%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

ATXI Stock Price Chart Interactive Chart >

Price chart for ATXI

ATXI Price/Volume Stats

Current price $0.25 52-week high $2.69
Prev. close $0.27 52-week low $0.20
Day low $0.25 Volume 217,900
Day high $0.28 Avg. volume 2,684,269
50-day MA $0.31 Dividend yield N/A
200-day MA $0.82 Market Cap 5.48M

Avenue Therapeutics, Inc. (ATXI) Company Bio


Avenue Therapeutics, Inc., a specialty pharmaceutical company, acquires, licenses, develops, and commercializes an intravenous formulation of tramadol HCI principally for use in the acute/intensive care hospital setting. Its product candidate is IV Tramadol for the treatment of post-operative pain. The company was founded in 2015 and is based in New York, New York.


ATXI Latest News Stream


Event/Time News Detail
Loading, please wait...

ATXI Latest Social Stream


Loading social stream, please wait...

View Full ATXI Social Stream

Latest ATXI News From Around the Web

Below are the latest news stories about Avenue Therapeutics Inc that investors may wish to consider to help them evaluate ATXI as an investment opportunity.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

Good morning, investors!

William White on InvestorPlace | March 8, 2022

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

Welcome back, trader!

William White on InvestorPlace | March 7, 2022

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

Rise and shine, trader!

William White on InvestorPlace | March 2, 2022

FDA's AdComm Says Avenue Therapeutics Submitted Insufficient Data On IV Tramadol

Avenue Therapeutics Inc (NASDAQ: ATXI) announced the outcome of the FDA meeting of the Anesthetic and Analgesic Drug Products Advisory Committee and the Drug Safety and Risk Management Advisory Committee on IV tramadol. The Advisory Committee had to vote on "has the Applicant submitted adequate information to support the position that the benefits of their product outweigh the risks for the management of acute pain severe enough to require an opioid analgesic in an inpatient setting?" The result

Yahoo | February 16, 2022

Avenue Therapeutics Announces Outcome of FDA Advisory Committee Meeting on IV Tramadol

NEW YORK, Feb. 15, 2022 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today announced the outcome of the U.S. Food and Drug Administration (“FDA”) joint meeting of the Anesthetic and Analgesic Drug Products Advisory Committee and the Drug Safety and Risk Management Advisory Committee on IV tramadol. In the final part of the public meeting, the Advisory Committee voted yes or no on

Yahoo | February 16, 2022

Read More 'ATXI' Stories Here

ATXI Price Returns

1-mo -13.79%
3-mo -46.04%
6-mo -73.12%
1-year -90.12%
3-year -95.95%
5-year -96.88%
YTD -72.47%
2021 -84.74%
2020 -38.02%
2019 77.78%
2018 49.17%
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.3919 seconds.